Literature DB >> 21931991

Ammonium pyrrolidine dithiocarbamate and RS 102895 attenuate opioid withdrawal in vivo and in vitro.

Ashish K Rehni1, Nirmal Singh.   

Abstract

RATIONALE: Recently, nuclear factor kappa B is indicated in the precipitation of opioid withdrawal syndrome. NF-κB activation is noted to control the transcription and biochemical activation of chemokines. Opioid receptor activation-linked chemokine stimulation is reported to mediate certain effects produced by prolonged opioid treatment. Ammonium pyrrolidine dithiocarbamate (APD) and RS 102895 are relatively selective inhibitors of NF-κB and C-C chemokine receptor 2, respectively.
OBJECTIVES: The present study investigates the effect of APD and RS 102895 on morphine withdrawal signs in vitro and in vivo.
MATERIALS AND METHODS: Morphine was administered twice daily for 5 days, following which a single day 6 injection of naloxone (8 mg/kg, i.p.) precipitated opioid withdrawal syndrome in mice. Withdrawal syndrome was quantitatively assessed in terms of withdrawal severity score and the frequency of jumping, rearing, fore paw licking and circling. Naloxone-induced contraction in morphine-withdrawn isolated rat ileum was employed as an in vitro model. An isobolographic study design was employed in the two models to assess potential synergistic activity between APD and RS 102895.
RESULTS: APD and RS 102895 dose-dependently attenuated naloxone-induced morphine withdrawal syndrome both in vivo and in vitro. APD was also observed to exert a synergistic interaction with RS 102895.
CONCLUSIONS: It is concluded that APD and RS 102895 attenuate morphine withdrawal signs possibly by a NF-κB and C-C chemokine receptor 2 activation pathway-linked mechanisms potentially in an interdependent manner.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21931991     DOI: 10.1007/s00213-011-2489-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  47 in total

Review 1.  Cellular and synaptic adaptations mediating opioid dependence.

Authors:  J T Williams; M J Christie; O Manzoni
Journal:  Physiol Rev       Date:  2001-01       Impact factor: 37.312

2.  CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates.

Authors:  Nazira El-Hage; Guanghan Wu; Jayakrishna Ambati; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmunol       Date:  2006-07-10       Impact factor: 3.478

3.  Modulation of src-kinase attenuates naloxone-precipitated opioid withdrawal syndrome in mice.

Authors:  Ashish K Rehni; Nirmal Singh
Journal:  Behav Pharmacol       Date:  2011-04       Impact factor: 2.293

Review 4.  Statistical analysis of drug-drug and site-site interactions with isobolograms.

Authors:  R J Tallarida; F Porreca; A Cowan
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

5.  [Effects of sinomenine on NO/nNOS system in cerebellum and spinal cord of morphine-dependent and withdrawal mice].

Authors:  Zhen Liu; Ji-Fang Zheng; Lu-Qing Yang; Lan Yi; Bi Hu
Journal:  Sheng Li Xue Bao       Date:  2007-06-25

6.  Expression of monocyte chemoattractant protein-1 in brain tissue of patients with intractable epilepsy.

Authors:  Y Wu; X Wang; X Mo; Z Xi; F Xiao; J Li; X Zhu; G Luan; Y Wang; Y Li; J Zhang
Journal:  Clin Neuropathol       Date:  2008 Mar-Apr       Impact factor: 1.368

7.  Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia.

Authors:  W Kelder; J C McArthur; T Nance-Sproson; D McClernon; D E Griffin
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

Review 8.  Nuclear factor kappaB signaling in opioid functions and receptor gene expression.

Authors:  Yulong L Chen; Ping-Yee Law; Horace H Loh
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-08       Impact factor: 4.147

9.  Morphine stimulates CCL2 production by human neurons.

Authors:  R Bryan Rock; Shuxian Hu; Wen S Sheng; Phillip K Peterson
Journal:  J Neuroinflammation       Date:  2006-12-08       Impact factor: 8.322

10.  Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line.

Authors:  K Matsushima; C G Larsen; G C DuBois; J J Oppenheim
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

View more
  5 in total

1.  Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.

Authors:  Ashish K Rehni; Nirmal Singh; Mahesh Rachamalla; Kulbhushan Tikoo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-25       Impact factor: 3.000

2.  MCP-1/CCR2 interactions direct migration of peripheral B and T lymphocytes to the thymus during acute infectious/inflammatory processes.

Authors:  Deborah L Hodge; Della Reynolds; Fabio M Cerbán; Silvia G Correa; Natalia S Baez; Howard A Young; Maria Cecilia Rodriguez-Galan
Journal:  Eur J Immunol       Date:  2012-08-15       Impact factor: 5.532

3.  In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.

Authors:  Prabhat Singh; Bhupesh Sharma; Surbhi Gupta; B M Sharma
Journal:  Psychopharmacology (Berl)       Date:  2014-07-26       Impact factor: 4.530

4.  The effect of inflammatory cell-derived MCP-1 loss on neuronal survival during chronic neuroinflammation.

Authors:  Andrew J Sawyer; Weiming Tian; Jennifer K Saucier-Sawyer; Paul J Rizk; W Mark Saltzman; Ravi V Bellamkonda; Themis R Kyriakides
Journal:  Biomaterials       Date:  2014-05-29       Impact factor: 12.479

5.  Suppression of vaccine immunity by inflammatory monocytes.

Authors:  Leah A Mitchell; Angela J Henderson; Steven W Dow
Journal:  J Immunol       Date:  2012-11-07       Impact factor: 5.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.